Finance JournalistFinance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
At least US$36.7 million was lost across four decentralised finance exploits in the past six months as attackers increasingly targeted unverified smart contracts whose source code was not publicly available, according to a new Chainalysis report.
dorsaVi (ASX:DVL) has entered into an agreement to license two breakthrough robotics intellectual property assets.
Solana Institute CEO Kristin Smith has urged the US Senate to preserve developer protections in the CLARITY Act, arguing that open-source developers and blockchain infrastructure providers should not be regulated as financial intermediaries.
Serko (ASX:SKO) announced an executive restructure designed to fast-track its strategic execution.
The US House of Representatives has introduced a group of bills aimed at changing how cryptocurrency activity is taxed across mining, staking, donations, and reporting.
Teleflex (NYSE:TFX) announced positive four-year follow-up data from its First-in-Human BIOMAG-I clinical trial, reinforcing the long-term safety and performance stability of its third-generation Freesolve Resorbable Magnesium Scaffold.
RedHill Biopharma (NASDAQ:RDHL) announced that the U.S. Food and Drug Administration has granted rare pediatric disease designation to its investigational asset, opaganib, for the treatment of neuroblastoma, a type of cancer that primarily affects infants and young children.
United Natural Foods (NYSE:UNFI) reported a return to profitability for the third quarter of fiscal year 2026, as targeted overhead reductions and warehouse optimization measures successfully offset a moderate contraction in top-line sales.
Nathan’s Famous (NASDAQ:NATH) reported higher top-line revenue for fiscal year 2026, driven by growth in its foodservice and franchise segments, even as surging input costs chipped away at overall profit margins ahead of its planned private ownership transition.
Zai Lab (NASDAQ:ZLAB) announced that China’s National Medical Products Administration has approved its Biologics License Application for TIVDAK, an injectable therapeutic targeting adult patients with recurrent or metastatic cervical cancer.
